中关村（SZ 000931，收盘价：5.56元）8月12日晚间发布公告称，近日，公司下属公司多多药业有限公 司收到国家药品监督管理局核准签发的《药品注册证书》，获悉，多多药业研制的"盐酸氨溴索注射 液"通过了药品注册审评审批。产品名称为"盐酸氨溴索注射液"。 2024年1至12月份，中关村的营业收入构成为：生物医药占比74.96%，混凝土占比17.48%，养老健康占 比4.94%，其他占比2.62%。 （文章来源：每日经济新闻） ...

关于下属公司多多药业盐酸氨溴索注射液获得《药品注册证书》的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-089 北京中关村科技发展（控股）股份有限公司 关于下属公司多多药业盐酸氨溴索注射液 获得《药品注册证书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 4 月披露《关于下属公司多多药业盐酸氨溴索注射液收到国家药品监督管理局< 受理通知书>的公告》（公告编号：2024-039）。 近日，公司下属公司多多药业有限公司（以下简称：多多药业）收到国家药 品监督管理局核准签发的《药品注册证书》（证书编号：2025S02440），获悉， 多多药业研制的"盐酸氨溴索注射液"（规格：2ml:15mg）通过了药品注册审 评审批。现将具体情况公告如下： 一、批件主要内容 药品名称：盐酸氨溴索注射液 剂型：注射剂 规格：2ml:15mg 第 1 页 关于下属公司多多药业盐酸氨溴索注射液获得《药品注册证书》的公告 共 3 页 注册分类：化学药品 4 类 申请事项：药 ...

关于控股股东一致行动人股份延长司法冻结期限及被轮候冻结的公告 共 3 页 $$\begin{array}{r l r l}{{\mathfrak{M}}}&{{}{\mathbf{1}}}&{{\mathbf{\nabla}\overline{{{\mathfrak{M}}}}}}\end{array}$$ 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 司法冻结 数量（股） 占其所持 股份比例 占公司总 股本比例 司法冻结 起始日 原司法冻 结到期日 司法冻结 到期日 （延期后） 司法冻结执行 人 国美电器 有限公司 是 5,540,167 11.08% 0.74% 2022-8-19 2025-8-18 2028-8-6 河南自由贸易 试验区郑州片 区人民法院注 一、控股股东一致行动人股份延长司法冻结期限的情况 二、控股股东一致行动人股份被轮候冻结的情况 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 本次被轮候 冻结数量 （股） 占其所持 股份比例 占公司 总股本 比例 是否 为限 售股 委托 日期 轮候 期限 轮候 机关 原因 国美电器 有限公司 是 50,000,000 100. ...

Core Viewpoint - The company, Zhongguancun, announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Ambroxol Hydrochloride Injection, which is expected to aid in respiratory health [1] Group 1 - The approved drug, Ambroxol Hydrochloride, is known for its properties that promote mucus clearance and dissolve secretions, thereby improving respiratory conditions [1] - The future production and sales of the drug may face uncertainties due to factors such as national policies and market environment [1]

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. has received the drug registration certificate for "Ambroxol Hydrochloride Injection" from the National Medical Products Administration, indicating successful approval for the drug's registration review and approval process [1] Group 1: Product Details - Ambroxol Hydrochloride has properties that promote mucus clearance and dissolve secretions, aiding in the expulsion of viscous secretions from the respiratory tract and improving respiratory conditions [1] - The injection is clinically applicable for abnormal mucus secretion and poor expectoration function in acute and chronic pulmonary diseases, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, and bronchial asthma [1] - It is also indicated for the preventive treatment of pulmonary complications after surgery and for the treatment of infant respiratory distress syndrome (IRDS) in premature and newborn infants [1] Group 2: Financial Investment - As of the announcement date, the company has invested a total of 2.0558 million yuan in the research and development of the generic drug registration application project for Ambroxol Hydrochloride Injection [1]

通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 7 月披露《关于下属公司多多药业盐酸曲马多注射液一致性评价申报收到国家药 品监督管理局<受理通知书>的公告》（公告编号：2024-058）。 近日，公司下属公司多多药业有限公司（以下简称：多多药业）收到国家药 品监督管理局核准签发的《药品补充申请批准通知书》（通知书编号： 2025B03681），获悉，多多药业生产的"盐酸曲马多注射液"（规格：2ml:100mg） 通过了仿制药质量和疗效一致性评价。现将具体情况公告如下： 一、批件主要内容 药品名称：盐酸曲马多注射液 关于下属公司多多药业盐酸曲马多注射液通过一致性评价的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-087 北京中关村科技发展（控股）股份有限公司 关于下属公司多多药业盐酸曲马多注射液 剂型：注射剂 规格：2ml:100mg 注册分类：化学药品 受理号：CYHB2450385 通知书编号：2025B03681 上市许可持有人 ...

Group 1 - The company has disclosed that Gome Electrical Appliances Holdings Limited, a significant shareholder, holds 50,000,000 circulating shares, accounting for 6.64% of the company's total shares [1][2] - Gome Electrical Appliances' shares have been newly subjected to court-ordered freezing, which is part of a broader situation involving the freezing of shares held by the controlling shareholder and its concerted actors [1][2] - As of August 7, 2025, the total number of shares frozen for the shareholder and its concerted actions is detailed, indicating ongoing legal and financial challenges [2] Group 2 - The company reassures that the freezing of shares will not lead to a change in control and that there are no non-operational fund occupations or illegal guarantees harming the company's interests [2] - The company maintains independence in assets, business, and finance from the controlling shareholder and its concerted actions, with no significant impact on governance or operations expected at this time [2] - The company is monitoring the situation closely, as the controlling shareholder faces heavy debt burdens and numerous lawsuits, which could potentially affect the stability of control if not managed properly [2]

关于控股股东一致行动人部分股份被轮候冻结的公告 关于控股股东一致行动人部分股份被轮候冻结的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-086 北京中关村科技发展（控股）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）通过 中国证券登记结算有限责任公司查询，获悉： 国美电器有限公司（以下简称：国美电器）作为公司控股股东国美控股集团 有限公司的一致行动人，现持有公司 50,000,000 股流通股，持股比例为 6.64%； 国美电器所持有公司的部分股份新增被法院轮候冻结，具体情况如下： 二、股东股份累计被冻结情况 （一）截至 2025 年 8 月 7 日，上述股东及其一致行动人所持被司法冻结股 份情况如下： | 股东名称 | | | 累计被司法冻 | 累计被标记 | 占其所持股 | 占公司 | | --- | --- | --- | --- | --- | --- | --- | | | 持股数量 | 持股比例 | 结股份数量 | 股份数量 | 份比例 ...

Core Viewpoint - The company stated that the gross margin of its biopharmaceutical segment aligns with the overall level of the pharmaceutical industry, indicating a commitment to maintaining growth and technological leadership through significant R&D investments, which currently depress overall net profit levels. The company anticipates that once R&D outcomes are converted into products, this will enhance the overall net profit of the biopharmaceutical segment [1]. Group 1 - The biopharmaceutical segment's gross margin is consistent with the pharmaceutical industry's average [1] - The company is investing heavily in R&D to ensure sustained growth and technological advancement [1] - Current R&D expenditures are temporarily lowering the overall net profit levels [1] Group 2 - The company expects that successful R&D outcomes will eventually translate into products, improving net profit levels in the biopharmaceutical segment [1]

Core Points - The company held its fourth temporary meeting of the ninth board of directors for the year 2025 on August 4, 2025, where all nine directors were present and voted unanimously on several resolutions [1][3][4]. Financing Guarantees - The company approved a guarantee for Shandong Huasu to apply for a financing credit of up to 46 million yuan from Bank of Communications, with collateral provided by Shandong Zhongguancun's industrial real estate and land use rights valued at 82.163 million yuan as of June 27, 2025 [2][3]. - A guarantee was also approved for Shandong Huasu to apply for a financing credit of up to 30 million yuan from Rizhao Bank, with collateral in the form of patents [4][7]. - The company approved a guarantee for Duoduo Pharmaceutical to apply for a financing credit of up to 10 million yuan from Jiamusi Rural Credit Cooperative, with a guarantee provided by the company’s subsidiary [8]. Lease Financing - The company’s subsidiary, Beijing Huasu, plans to engage in a sale-leaseback financing lease with Jiangsu Financial Leasing, using production equipment valued at approximately 45.4187 million yuan as collateral, with a financing limit of up to 30 million yuan for a term not exceeding two years [10][11]. Joint Venture - The company plans to establish a joint venture with two other partners, contributing a total registered capital of 1 million yuan, with the company holding a 67% stake [13]. Shareholder Meeting - The company announced the convening of its fifth temporary shareholder meeting for the year 2025 [15].